Aclaris slumps as Phase IIa study of oral zunsemetinib disappoints

7 March 2023
aclaris-tx-large

Shares of Aclaris Therapeutics (Nasdaq: ACRS) closed down almost 45% at $7.07 yesterday, as the company said its zunsemetinib did not meet its primary and secondary efficacy endpoints in a Phase IIa study evaluating the investigational drug in patients with moderate to severe hidradenitis suppurativa.

Hidradenitis suppurativa, also known as acne inversa, is a chronic skin condition featuring painful nodules and abscesses under the skin that can enlarge and drain pus.

The only drug currently approved to treat the disease is AbbVie’s (NYSE: ABBV) Humira (adalimumab), but Novartis (NOVN: VX) is moving to get its interleukin (IL)-17 therapy Cosentyx (secukinumab) approved as an option.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology